On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved Polatuzumab Vedotin-Piiq in combination with a rituximab product,…
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the…
By Dr. Dipesh Uprety Karmanos Cancer Institute Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab,…
By Dr. Abdurahman Alloghbi King Khalid University, Saudi Arabia The Middle East and North Africa (MENA) region spans 22…
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Attainment of pathological complete response (pCR) of breast cancer is…
On April 3, 2023, the U.S. Food and Drug Administration approved enfortumab vedontin-ejfv with pembrolizumab for patients with locally advanced…
On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or…
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone…
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody…